This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Ram Madasu, MD; Michael J. Ruckenstein, MD, MSc, FRCSC; Fannie Leake, MA, CCC-A; Elaine Steere, PhD; K. Thomas Robbins, MD

Arch Otolaryngol Head Neck Surg. 1997;123(9):978-981.

Abstract
Objective
To assess the incidence and magnitude of ototoxicity in patients undergoing an experimental targeted chemoradiation protocol incorporating extremely high-dose intra-arterial cisplatin therapy with systemic sodium thiosulfate neutralization for the treatment of advanced carcinomas of the head and neck.

Design
Inception cohort study.

Setting
University-based, tertiary care referral center for advanced head and neck malignant disease.

Patients
The first 70 patients with advanced carcinomas of the head and neck consecutively entered in the protocol.

Intervention
Patients received up to 4 weekly courses of intra-arterial cisplatin (150 mg/m² per infusion), together with systemic sodium thiosulfate and external beam radiation (68-70 Gy). Audiometric analysis was performed before the initiation of therapy, and subsequent to the second and fourth cisplatin infusions.

Main Outcome Measures
Audiometric thresholds. Ototoxicity was defined as an increase in pure-tone threshold of 15 dB at 1 frequency or 10 dB at 3 frequencies, between 250 and 4000 Hz.

Results
The incidence of ototoxicity was 25% at 150 mg/m², 50% at 300 mg/m², 64% at 450 mg/m², and 60% at 600 mg/m². Hearing at frequencies of 2000 Hz or less was minimally or not affected. Previous hearing loss did not appear to affect the incidence of ototoxicity. A plateau of hearing loss at 60-dB hearing level, as noted by other authors, was not observed. There were no cases of debilitating tinnitus or of vestibular loss.

Conclusions
Ototoxicity did occur but was largely confined to the higher frequencies. Hearing losses resulting from this chemoradiation protocol were not sufficiently severe to alter its application.

Arch Otolaryngol Head Neck Surg. 1997;123:978-981

Author Affiliations
From the Department of Otolaryngology, Head and Neck Surgery, University of Tennessee, Memphis.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Ototoxicity in a Randomized Phase III Trial of Intra-Arterial Compared With Intravenous Cisplatin Chemoradiation in Patients With Locally Advanced Head and Neck Cancer
Zuur et al.
JCO 2007;25:3759-3765.
ABSTRACT | FULL TEXT  

RADPLAT: An Alternative to Surgery?
Alkureishi et al.
The Oncologist 2006;11:469-480.
ABSTRACT | FULL TEXT